Pathogenic role of intestinal microflora changes in patients with irritable bowel syndrome and treatment options
Abstract
The aim of review. To analyse of publications on qualitative and quantitative changes in pattern of intestinal microflora in patients with irritable bowel syndrome (IBS) and options of its treatment by pre-, pro-, and symbiotic drugs.
Key points. In the last years more and more data appear on changes in qualitative and quantitative spectrum of intestinal microflora in combination to low degree inflammation of colonic mucosa at IBS that allowed to reconsider standard concepts on pathogenesis of this functional disorder. Agents restoring intestinal microflora balance are effective for symptom relief of this disease.
Conclusion. The analysis of the information concerning disorder of qualitative and quantitative structure of intestinal microflora at IBS, mechanisms of action of pre-, pro- and synbiotics, allows to expand essentially treatment options of this disease.
About the Authors
Ye. A. Poluektova
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university» Ministry of Healthcare of Russia
Russian Federation
Russian Federation
Poluektova Yelena A — MD, leading research associate of Scientific Research Department of innovative therapy, doctor of department of chronic bowel and pancreatic diseases
119991, Moscow, Pogodinskaya street, 1, bld 1
S. Yu. Kuchumova
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university» Ministry of Healthcare of Russia
Russian Federation
Russian Federation
O. S. Shifrin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university» Ministry of Healthcare of Russia
Russian Federation
Russian Federation
A. A. Sheptulin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university» Ministry of Healthcare of Russia
Russian Federation
Russian Federation
V. T. Ivashkin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university» Ministry of Healthcare of Russia
Russian Federation
Russian Federation
References
1. Ивашкин В.Т., Шептулин А.А., Склянская О.А. Синдром диареи. М.: ГЭОТАР-Медиа; 2002. С. 58-63.
2. Кучумова С.Ю., Полуэктова Е.А., Шептулин А.А., Ивашкин В.Т. Физиологическое значение кишечной микрофлоры. Рос журн гастроэнтерол гепатол коло проктол 2011; 21(5); 5-9.
3. Пробиотики и пребиотики. Всемирная гастроэнтерологическая ассоциация. Практические рекомендации; Май 2008.
4. Рязанский С.С., Гвоздев В.А. Короткие РНК и канцерогенез. Биохимия 2008; 73(5); 640-55.
5. Arumugam M, et al. Enterotypes of the human gut microbiome Nature 2011; 473 (7346):174-80.
6. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaële N, et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 2012; 7(8).
7. Bertiaux-Vandaële N, Youmba SB, Belmonte L, et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol 2011; 106 (12):2165-73.
8. Bittner AC, Croffut RM, Stranahan MC. Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin Ther 2005; 27:755-61.
9. Claesson MJ, Cusack S, O’Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011; 108 (suppl. 1:45):86-91.
10. Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: probiotics for the treatment of irritable bowel syndrome – focus on lactic acid bacteria. Aliment Pharmacol Ther 2012; 35(4):403-13.
11. Codling C, O’Mahony L, Shanahan F, et al. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010; 55:392-7.
12. Colecchia A, Vestito A, La Rocca A, et al. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol 2006; 52:349-58.
13. Comelli EM, Simmering R, Faure M, et al. Multifaceted transcriptional regulation of the murine intestinal mucus layer by endogenous microbiota. Genomics 2008; 91:70-7.
14. Dalmasso G, Nguyen HT, Yan Y, et al. Microbiota modulate host gene expression via microRNAs. PLoS One 2011; 6(4).
15. De Filippo C, Cavalieri D, di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010; 107(33):146-9.
16. Drossman DA. Rome III: the new criteria. Chin J Dig Dis
17. ; 7(4):181-5.
18. Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, Flint HJ, Dieleman LA, Ringel Y, Guandalini S, Kelly CP, Brandt LJ. Recommendations for probiotic use – 2011 update. J Clin Gastroenterol
19. ; 45:168-71.
20. Greer JB, O’Keefe SJ. Microbial induction of immunity, inflammation, and cancer. Front Physiol 2011; 1:168.
21. Hosseini A, Nikfar S, Abdollahi M. Probiotics use to treat irritable bowel syndrome. Expert Opin Biol Ther 2012; 10:23-34.
22. Hoveyda N, et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9(15).
23. Hsu PW, Huang HD, Hsu SD, Lin LZ, Tsou AP, Tseng CP, Stadler PF, Washietl S, Hofacker IL. miRNAMap: genomic maps of microRNA genes and their target genes in mammalian genomes. Nucleic Acids Res 2006; 34:135-9.
24. Huttenhower C, et al. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486(7402):207-14.
25. Juntunen M, et al. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol 2001; 8(suppl. 2):293-6.
26. Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower bifidobacteria counts in both duodenal mucosaassociated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15(28):87-92.
27. Khachatryan ZA, Ktsoyan ZA, Manukyan GP, et al. Predominant role of host genetics in controlling the composition of gut microbiota. PLoS ONE 2008; 3:3064
28. Khan MW, Kale AA, Bere P, Vajjala S, Gounaris E, Pakanati KC. Microbes, intestinal inflammation and probiotics. Expert Rev Gastroenterol Hepatol 2012; 6(1):81-94.
29. Kontula P, Nollet L, Saarela M, et al. The effect of lactulose on the survival of Lactobacillus rhamnosus in the simulator of the human intestinal microbial ecosystem (SHIME) and in vivo. Microbial Ecology Health Dis In Press 1999.
30. Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011; 17:25266.
31. Longstreth GF, Thompson WG, et al. Funcional bowel disorders. Gastroenterology 2006; 130:1490-1.
32. Malinen E, Rinttilä T, Kajander K, et al. Analysis of the microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100:373-82.
33. Merenstein D, Murphy M, et al. Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, clusterrandomized, placebo-controlled, clinical trial. Eur J Clin Nutr 2010; 64(7):669-77.
34. Moayyedi P, Ford A, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59(3):325-32.
35. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009; 15:300-10.
36. Ohland С, MacNaughton К. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointestinal Liver Physiol 2010; 298(6):807-19.
37. O’Mahony L, Mccarthy J, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128(3):541-51.
38. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci USA 2010; 107:454-9.
39. Parkes GC, Rayment NB, Hudspith BN, et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 2012; 24:31-9.
40. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95(12):3503-6.
41. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98(2):412-9.
42. Prakash S, et al. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 2011; 5:71-86.
43. Pujol P, et al. The effect of fermented milk containing Lactobacillus casei on the immune response to exercise. Training Rehab 2000; 9:209-23.
44. Qin J, Li R, Raes J, Arumugam M, et al. A human gut microbial gene catalogue established by metagenomic sequencing MetaHIT Consortium. Nature 2010; 464(7285):59-65.
45. Rajilić-Stojanović М, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141(5):1792-801.
46. Rambaud J-C, et al. Gut Microflora. Digestive physiology and pathology. John Libbey Eurotext. Paris; 2006.
47. Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci 2010; 55:2441-9.
48. Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10(12):1802-5.
49. Silk DB, Davis A, Vulevic J, et al. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29:508-18.
50. Singh N, et al. The murine caecal microRNA signature depends on the presence of the endogenous microbiota. Int J Biol Sci 2012; 8(2):171-86.
51. Steer T, Carpenter H, Tuohy K, Gibson GR. Perspectives on the role of the human gut microbiota and its modulation by pro and prebiotics. Nutr Res Rev 2000; 13(2):229-54.
52. Taganov KD, Boldin MP, Baltimore D. MicroRNAs and immunity: tiny players in a big field. Immunity 2007; 26(2):133-7.
53. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22(5):512-9.
54. Tap J, Mondot S, et al. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 2009; 11(10):2574-84.
55. Tynkkynen S, Satokari R, Saarela M, et al. Comparison of ribotyping, randomly amplified polymorphic DNA analysis and pulsed-field gel electrophoresis in typing of Lactobacillus rhamnosus and L. casei strains. Appl Environ Microbiol 1999; 65:3908-14.
56. Vanderhoof JA, Young R. Probiotics in the United States. Clin Infect Dis 2008; 1 (suppl. 2):67-72.
57. Veiga P, et al. Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes. Proc Natl Acad Sci USA 2010; 107(42):18132-7.
58. Zhou Q, et al. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 2010; 59(6):775-84.
Review
For citations:
Poluektova Ye.A., Kuchumova S.Yu., Shifrin O.S., Sheptulin A.A., Ivashkin V.T. Pathogenic role of intestinal microflora changes in patients with irritable bowel syndrome and treatment options. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(3):89-97. (In Russ.)
Views:
95
Email this article 
